Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Certain advanced technologies, such as 3D displays, biosensing, and security printing, can utilize circularly polarized ...

In a blog post, the tech giant introduced new features for Google Workspace users. The company had earlier ditched the Gemini add-on and integrated the AI features within the Workspace subscription.

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

There are two styles to choose from: the default, Animation, which is like a 3D image; and Illustration, which is more flat and cartoony. Apple might add more styles in the future. There's also an ...

Whether you’re looking to find a friend’s profile, checking to see if anyone is infringing on your copyrighted images, or hunting down the source of a viral meme, Facebook reverse image ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

SAN FRAN­CIS­CO — Just over 20 years ago, the peo­ple of Cal­i­for­nia vot­ed to spend bil­lions of dol­lars on an ex­cit­ing new idea to re­make med­i­cine … ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities ...

Fianlimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate ...